Tesofensine

Tesofensine is not a peptide; it is a small-molecule triple monoamine reuptake inhibitor. While marketed by some wellness clinics and supplement vendors as a “peptide” for weight loss due to its use in clinical trials, it is scientifically classified as a phenyltropane derivative.

Key Benefits

• May help support appetite control and reduced food cravings
• Commonly researched for weight management and fat loss support
• May promote increased energy expenditure and metabolic activity
• Research suggests potential benefits for improving focus and mood during weight management programs

FDA-Approved Uses

IMPORTANT NOTE: Tesofensine is NOT a peptide. It is a small-molecule drug (triple monoamine reuptake inhibitor / TMRI). It is included in this document as it is widely discussed in the peptide and weight management research community.

Originally developed by NeuroSearch (Denmark) for neurological conditions; repurposed for obesity after significant weight loss was observed in trial participants.

Original investigational indications (unsuccessful):
1. Parkinson’s disease — clinical development discontinued
2. Alzheimer’s disease — clinical development discontinued

Current investigational indication (Phase 2 completed, Phase 3 ongoing):
3. Obesity / Overweight — primary current focus
Phase 2 results: 10.6% mean weight loss at 0.5 mg over 24 weeks vs. 2% placebo
4. Type 2 Diabetes — secondary investigation

FDA status: Investigational New Drug (IND); not approved for commercial sale. Phase 3 trials ongoing; timeline for FDA submission and approval remains uncertain.
Regulatory note: Tesofensine has NOT been rejected by the FDA — it has not yet completed Phase 3 and submitted an NDA.

Trade Names in USA and Manufacturers

No FDA-approved trade name in the USA.

Developer: NeuroSearch A/S (Denmark) — original developer
Development has been licensed/transferred; current development status involves multiple parties.

US availability:
– Cannot be legally prescribed (not FDA-approved)
– Used off-label in some US wellness/weight loss clinics despite lack of FDA approval
– Available from compounding pharmacies in some states (legal status varies; verify with counsel)
– Research chemical vendors (not for human use)

Also known as: NS2330

Dosage

⚠️ No FDA-approved dosing. The following reflects Phase 2 clinical trial doses only.

Phase 2 clinical trial doses (oral capsule, once daily):
0.25 mg/day — lowest studied dose
0.5 mg/day — best efficacy/safety balance in Phase 2
1.0 mg/day — higher weight loss but more cardiovascular effects

Oral administration — no reconstitution required (solid oral capsule/tablet)

Phase 2 weight loss results by dose:
0.25 mg: ~4.5% placebo-subtracted weight loss (24 weeks)
0.5 mg: ~9.2% placebo-subtracted weight loss (24 weeks)
1.0 mg: ~10.6% placebo-subtracted weight loss (24 weeks)

All participants in Phase 2 instructed to maintain 300 kcal/day deficit and increase physical activity.

Pricing

No commercial (FDA-approved) pricing.

Off-label / compounded sources (where legally available, with prescription):
~$100–$300/month (varies widely by clinic and pharmacy)

Research peptide/chemical vendors (unregulated):
~$50–$150/month
[Not recommended — unregulated; safety not guaranteed]

Note: Tesofensine has no shortage-list status, no compounding exemption, and is not peptide-based — no established legal compounding pathway in most states.

Tips

– Tesofensine is NOT a peptide — it is a small-molecule triple reuptake inhibitor. Understand the mechanism before comparing to GLP-1 therapies.
– Tesofensine has not been FDA-rejected — it simply has not yet completed Phase 3 and submitted an NDA. Monitor trial progress for any FDA submission announcement.
– The main cardiovascular safety concern (heart rate elevation ~7 bpm) has been a key regulatory focus — patients with hypertension or cardiovascular risk factors should exercise particular caution.
– Unlike GLP-1 drugs (semaglutide, tirzepatide), tesofensine’s primary side effects are dry mouth and insomnia rather than nausea/vomiting — a distinct profile that may suit some patients better.
– The stimulant-like mechanism (dopamine/norepinephrine) raises questions about tolerance and dependency that do not apply to GLP-1 agents — discuss with your physician.
– FDA-approved weight loss medications (semaglutide, tirzepatide, liraglutide, naltrexone/bupropion, phentermine/topiramate) are available now with insurance support. Consider these before pursuing unapproved options.

Side Effects

From Phase 2 clinical trials (most complete human dataset available):

Most common:
– Dry mouth (xerostomia): Most frequently reported; dose-dependent; related to noradrenergic activity
– Insomnia / sleep disturbance: Dopamine and norepinephrine elevation can disrupt sleep; dose-dependent
– Nausea
– Headache
– Constipation
– Diarrhea

Cardiovascular (primary safety concern):
– Elevated heart rate: Mean increase of ~7–8 bpm at therapeutic doses (0.5–1.0 mg)
– Blood pressure changes: Minimal at lower doses; requires monitoring at higher doses
– Overall withdrawal rate in Phase 2 due to adverse events: 13% (vs. 6% placebo)

Less common:
– Anxiety / nervousness (stimulant-like properties)
– Palpitations

Note: Unlike GLP-1 medications, nausea and vomiting are less prominent. Cardiovascular effects are the primary concern distinguishing it from GLP-1 class.

Contraindications

No formal contraindications established (no approved label).

Based on Phase 2 trial exclusion criteria and pharmacology:
– Cardiovascular disease: Elevated heart rate risk makes this a significant concern; patients with arrhythmias, uncontrolled hypertension, or significant CV disease should avoid
– Concurrent use of MAOIs, SSRIs, SNRIs, or other serotonergic/dopaminergic drugs: Risk of serotonin syndrome or excessive monoamine elevation — contraindicated
– History of substance abuse: Dopamine reuptake inhibition raises abuse potential concerns (though lower than classical stimulants at therapeutic doses)
– Psychiatric conditions (bipolar disorder, schizophrenia, anxiety disorders): Dopamine/norepinephrine elevation may worsen symptoms
– Pregnancy and breastfeeding: No safety data; not recommended
– Hypersensitivity to tesofensine or its components
– Children and adolescents: Not studied

Pharmacology

Tesofensine (NS2330) is a synthetic small-molecule drug — NOT a peptide. It is a triple monoamine reuptake inhibitor (TMRI) that inhibits presynaptic reuptake transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT) simultaneously. Developed as an oral capsule (once daily). Originally developed by NeuroSearch A/S (Denmark). Shares some pharmacological similarity with sibutramine (withdrawn from US market) and the antidepressant class of SNRIs, but with the additional dopaminergic component. Long plasma half-life enabling once-daily dosing. At therapeutic doses, produces less stereotypy and abuse potential than classical dopaminergic stimulants, though dependency and tolerance risks have not been fully characterized in long-term human studies.

Mechanism of action

Triple Monoamine Reuptake Inhibition:

Tesofensine simultaneously blocks three monoamine reuptake transporters:
1. SERT (Serotonin Transporter): Inhibiting serotonin reuptake increases synaptic serotonin → contributes to appetite suppression and mood effects (similar mechanism to SSRIs).
2. NET (Norepinephrine Transporter): Inhibiting norepinephrine reuptake increases synaptic norepinephrine → increases energy expenditure, thermogenesis, and appetite suppression (similar to SNRIs, sibutramine).
3. DAT (Dopamine Transporter): Inhibiting dopamine reuptake increases synaptic dopamine → enhances satiety signaling, reward processing, and motivational effects on eating behavior.

Additional mechanism:
– Indirectly potentiates cholinergic neurotransmission → possible beneficial effects on cognition (learning and memory) observed in animal models.

Net result: Reduced appetite, increased metabolic rate (thermogenesis), and modified reward responses to food — producing weight loss through central nervous system pathways distinct from GLP-1/amylin mechanisms.

Key distinction from GLP-1 drugs: Tesofensine acts centrally on neurotransmitter systems; GLP-1 drugs act peripherally (gut/pancreas) and centrally (hypothalamus via GLP-1 receptors). These are entirely different mechanisms.

Result Claims By Different Companies

NeuroSearch A/S (based on Phase 2 clinical trial data):

– Phase 2 TIPO-1 trial (Astrup et al., published Lancet 2008 — 203 patients, 24 weeks):
Weight loss results (placebo-subtracted):
0.25 mg: 4.5% | 0.5 mg: 9.2% | 1.0 mg: 10.6%
Weight loss at 0.5–1 mg was approximately double that of FDA-approved obesity medications available at the time of publication (2008).
Generally well-tolerated; dry mouth and insomnia most common; heart rate increase noted at higher doses.

– Phase 2B data (203 patients):
Mean weight loss of 6.5–12% across all dose groups over 24 weeks.
Cardiovascular: No clinically significant cardiovascular adverse events per FDA criteria at therapeutic doses, per NeuroSearch statement. However, increased heart rate and some blood pressure effects noted at 0.5 mg and 1.0 mg.

⚠️ No Phase 3 data publicly available as of May 2026. Tesofensine is NOT FDA-approved. Phase 2 data, while promising, does not establish safety or efficacy sufficient for regulatory approval. All claims above are from clinical trials; results should be interpreted cautiously.

Disclaimer

This content about “Tesofensine” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.